Clinical Utility of CD23 and FMC7 Antigen Coexistent Expression in B-Cell Lymphoproliferative Disorder Subclassification

Clinical Cytometry

Volumn 50, Issue 1, 2002, Pages 1-7

  Ahmad, Ejaz ^a   Garcia, Diana ^a   Davis, Bruce H ^a,b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b Maine Medical Center Research Institute   (United States)

Author keywords

Diagnostic immunology; Disease classification; Flow cytometry; Immunophenotype; Leukemia; Lymphoma; Monoclonal gammopathy; Phenotype

Indexed keywords

B LYMPHOCYTE ANTIGEN; CD23 ANTIGEN; CD5 ANTIGEN; FMC7 ANTIGEN; UNCLASSIFIED DRUG; FMC7 PROTEIN, HUMAN; GLYCOPROTEIN; IMMUNOGLOBULIN E RECEPTOR; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RELIABILITY; REPRODUCIBILITY; WALDENSTROEM MACROGLOBULINEMIA; ALGORITHM; BONE MARROW CELL; CLASSIFICATION; LYMPH NODE; METABOLISM; PATHOLOGY; RETROSPECTIVE STUDY;

ALGORITHMS; ANTIGENS, NEOPLASM; BONE MARROW CELLS; GLYCOPROTEINS; HUMANS; IMMUNOPHENOTYPING; LYMPH NODES; LYMPHOMA, B-CELL; RECEPTORS, IGE; RETROSPECTIVE STUDIES;

EID: 0037085336     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/cyto.10045     Document Type: Article

References (31)

1. Jennings CD, Foon KA. Recent advances in flow cytometry: applications to the diagnosis of hematologic malignancy. Blood 1997;90:2863-2892.
2. Davis BH, Foucar K, Szczarkowski W, Ball E, Witzig T, Foon KA, Wells D, Kotylo P, Johnson R, Hanson C, Bessman D. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: medical indications. Cytometry 1997;30:249-263.
3. Braylan RC, Orfao A, Borowitz MJ, Davis BH. Optimal number of reagents required to evaluate hematolymphoid neoplasias. Results of an international consensus meeting. Cytometry 2001;46:23-27.
4. Fournier S, Delespesse G, Rubio M, Biron G, Sarfati M. CD23 antigen regulation and signaling in chronic lymphoma leukemia. J Clin Invest 1992;89:1312-1321.
5. Fournier S, Rubio M, Delespesse G, Sarfati M. Role of low-affinity receptor for IgE (CD23) in normal and leukemia B-cell proliferation. Blood 1994;84:1881-1886.
6. Drexler HG, Menon M, Gaedicke G, Minowada J. Expression of FMC-7 antigen and tartrate resistant acid phosphotase enzyme in case of B-lymphoproliferative disorder. Eur J Cancer Clin Oncol 1987;23:61-68.
7. Zola H, Moore HA, Hohmann A, Houter IK, Nikoloutsopoulos A, Bradley J. The antigen of mature human B-cells detected by the monoclonal antibody FMC7: studies on the nature of this antigen and modulation of its expression. J Immunol 1984;133:321-326.
8. DiGiuseppe JA, Borowitz MJ. Clinical utility of flow cytometry in the chronic lymphoid leukemias. Semin Oncol 1998;25:6-10.
9. Huh YO, Pugh WC, Kantarjuan HM, Stass SA, Ma AC, Trujillo JM, Keating MJ. Detection of subgroups of chronic B-cell leukemias by FMC7 monoclonal antibody. Am J Clin Pathol 1994;101:283-289.
10. Garcia CP, Rooney MT, Ahmad E, Davis BH. Diagnostic usefulness of CD23 and FMC-7 antigen expression in B-cell lymphoma classification. Am J Clin Pathol 2001;115:258-265.
11. Stelzer GT, Shults KE, Loken MR. CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Ann N Y Acad Sci 1993;677:265-280.
12. Hubl W, Iturraspe J, Braylan RC. FMC7 antigen expression on normal and malignant B-cells can be predicted by expression of CD20. Cytometry 1998;34:71-74.
13. Serke S, Schwaner I, Yordanova M, Szczepek A, Huhn D. Monoclonal antibody FMC7 detects a conformation epitope on the CD20 molecule: evidence from phenotyping after Rituxan therapy and transfectant cell analyses. Cytometry 201;46:98-104.
14. D'Hautcourt JL, Isaac J. Mean fluorescence intensity of dual stained cells. Cytometry 1999;38:44-45.
15. Thakhi A, Edinger M, Myles J, Pohlman B, Tubbs R. Flow cytometric immunophenotyping of non-Hodgkin's lymphomas and related disorder. Cytometry 1996;25:113-124.
16. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary M, Delsol G, De Wolf-Peeters C, Brunangelo F, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralkiaer E, Warnke RA. A revised European American classification of lymphoid neoplasm: a proposal from an international study group. Blood 1994;84:1361-1392.
17. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J. Lymphoma clasification - from controversy to consensus: the R.E.A.L. and WHO classification of lymphoid neoplasms. Ann Oncol 2000 (11 Suppl);1:3-10.
18. Cheson BD, Bennet JM, Grever MJ, Kay N, Keating MJ, O'Brien J, Rai KR. National Cancer Institute - sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997.
19. Batata A, Shen B. Immunophenotyping of subtypes of B-chronic (mature) lymphoid leukemia: a study of 242 cases. Cancer 1992;70:2436-2443.
20. Huang JC, Finn WG, Goolsby CK, Variakojis D, Peterson LC. CD5-small B-cell leukemias are rarely classifiable as chronic lymphocytic leukemia. Am J Clin Pathol 1999;111:123-130.
21. Kilo MN, Dorfman DM. The utility of flow cytometric immunophenotypic analysis in the distinction of small lymphocytic lymphoma chronic lymphocytic leukemias from mantle cell lymphoma. Am J Clin Pathol 1996;105:451-457.
22. Matures E, Owusu-Ankomah K, Morilla R, Marco JG, Houlihan A, Que TH, Catovsky D. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994;8:1640-1645.
23. Dorfman DM, Pinkus GS. Distinction between small lymphocytic and mantle cell lymphoma by immunoreactivity for CD23. Mod Pathol 1994;7:326-331.
24. Hassan IB, Hayberg H, Sundstrom C. Immunophenotype of hairy cell leukemia. Eur J Hematol 1990;45:172-176.
25. Melo JV, Robinson DSF, Gregory C, Catovsky D. Splenic B-cell lymphoma with "villous" lymphocytes in the peripheral blood: a disorder distinct from hairy cell leukemia. Leukemia 1997;1:294-298.
26. Shapiro JL, Miller ML, Pohlman B, Mascha E, Fishleder AJ. CD5-B-cell lymphoproliferative disorder presenting in blood and bone marrow: a clinicopathologic study of forty - patients. Am J Clin Pathol 1999;111:477-487.
27. Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan T. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest oncology group study. Blood 1995;85:1075-1082.
28. Stein H, Lennert K, Feller AC, Mason DY. Immunohistochemical analysis of human lymphoma: correlation of histologic and immunological categories. Adv Cancer Res 1984;42:67-147.
29. Campo E, Miguel R, Jaffe ES. Primary nodal marginal zone lymphoma of splenic and MALT type. Am J Surg Pathol 1999;23:59-68.
30. Matutes E, Morilla R, Catovsky D. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with B-cell disorder. Blood 1994;83:1558-1562.
31. Hollema H, Poppema S. Immunophenotype of malignant lymphoma centroblastic-centrocytic, and malignant lymphoma centrocytic: an immunologic study indicating a derivation from different stages of B-cell differentiation. Hum Pathol 1988;19:1053-1059.